Get the Stockscreener App
11.79
0.83%
-0.07
Olema Pharmaceuticals Inc stock is traded at $11.79, with a volume of 111.61K.
It is down -0.83% in the last 24 hours and up +1.39% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$11.86
Open:
$11.78
24h Volume:
111.61K
Relative Volume:
0.24
Market Cap:
$680.32M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-4.8921
EPS:
-2.41
Net Cash Flow:
$-83.73M
1W Performance:
-0.83%
1M Performance:
+1.39%
6M Performance:
+10.23%
1Y Performance:
-29.11%
1-Day Range:
$11.68
$12.05
1-Week Range:
$11.18
$12.18
52-Week Range:
$8.51
$17.79
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of “Buy” by Brokerages - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation - Yahoo Finance
Possible Bearish Signals With Olema Pharmaceuticals Insiders Disposing Stock - Simply Wall St
SG Americas Securities LLC Acquires Shares of 13,056 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals (NASDAQ:OLMA) Earns Buy Rating from HC Wainwright - MarketBeat
Olema Pharmaceuticals maintains Buy rating from H.C. Wainwright By Investing.com - Investing.com UK
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 - The Manila Times
Insider Selling: Paradigm Biocapital Advisors L, Olema Pharmaceuticals Inc [OLMA] 10% Owner divested 2,400,000 shares – Knox Daily - Knox Daily
Closing Bell Recap: Olema Pharmaceuticals Inc (OLMA) Ends at 11.26, Reflecting a -1.23 Downturn - The Dwinnex
Can you still get a good price for Olema Pharmaceuticals Inc (OLMA) Shares at this point? - US Post News
Renaissance Technologies LLC Buys Shares of 53,200 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Point72 Asset Management L.P. Purchases New Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Aurigene Oncology, Olema Pharmaceuticals identify KAT6A inhibitors - BioWorld Online
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $27.00 - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Dimensional Fund Advisors LP - Defense World
OLMA Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
OLMA underperforms with a -4.07 decrease in share price - US Post News
74,657 Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Acquired by Dana Investment Advisors Inc. - MarketBeat
olema pharmaceuticals, inc. Earnings dates - RTTNews
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 3.8% - MarketBeat
Keeping an Eye on Olema Pharmaceuticals Inc (OLMA) After Insider Trading Activity - Knox Daily
Insider’s View: Deciphering Olema Pharmaceuticals Inc (OLMA)’s Financial Health Through Ratios - The Dwinnex
Long Term Trading Analysis for (OLMA) - Stock Traders Daily
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Marshall Wace LLP - Defense World
Ensign Peak Advisors Inc Acquires 850 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Affinity Asset Advisors LLC Purchases Shares of 275,000 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Affinity Asset Advisors LLC Invests $2.98 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Rhumbline Advisers Buys 17,953 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Logos Global Management LP - Defense World
Great Point Partners LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Great Point Partners LLC Purchases New Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Examining the Potential Price Growth of Olema Pharmaceuticals Inc (OLMA) - Knox Daily
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.3% - Defense World
Taking the lead: Olema Pharmaceuticals Inc (OLMA) - SETE News
A Tale of Resilience: Olema Pharmaceuticals Inc Amid Stock Market Turbulence - The InvestChronicle
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Position Boosted by Bank of New York Mellon Corp - MarketBeat
Bank of New York Mellon Corp Acquires 58,622 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Market Insight: Olema Pharmaceuticals Inc (OLMA)’s Notable Gain, Closing at 12.27 - The Dwinnex
Olema Pharmaceuticals Inc’s results are impressive - US Post News
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Victory Capital Management Inc. - Defense World
Victory Capital Management Inc. Has $8.38 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Analysts Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $27.00 - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Goldman initates Olema Pharmaceuticals Inc (OLMA) rating to a Buy - Knox Daily
Goldman Sachs maintains Buy rating on Olema Pharma shares with consistent target - Investing.com Canada
The Potential Rise in the Price of Olema Pharmaceuticals Inc (OLMA) following insiders activity - Knox Daily
Are Olema Pharmaceuticals Inc (OLMA) shares a good deal now? - US Post News
Candriam S.C.A. Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):